Search the Newsreel

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, HC Wainwright Analyst Says

Arrowhead Pharmaceuticals (ARWR) Stock Retreats As Losses Deepen Behind Phase III Progress

Arrowhead Pharmaceuticals (ARWR) stock dropped 3% after reporting a widening net loss of US$194.3m in Q3 2026, despite increased revenue and positive Phase III trial results for plozasiran. The market reacted to the deepening losses, while long-term investors are likely weighing the R&D spend …

Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $110.2, Implies 23% Upside

Arrowhead Pharmaceuticals, Inc. (ARWR) has seen its average 12-month price target raised from $107.6 to $110.2 by 10 analysts, suggesting a 23% potential upside from its August 4th closing price. The consensus rating for the stock remains a "Buy" among 14 covering analysts, with …

ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG

By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Acquires PRV to Accelerate sNDA Process for Plozasiran in sHTG On August 4, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced it signed an asset purchase agreement with an undisclosed party …

Countdown to Arrow Electronics (ARW) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Wall Street analysts forecast that Arrow Electronics (ARW) will report quarterly earnings of $4.45 per share in its upcoming release, pointing to a year-over-year increase of 83.1%. It is anticipated that revenues will amount to $9.45 billion, exhibiting an increase of 24.7% compared to …

Is Arrow Electronics’ (ARW) Akamai Partnership Enough To Offset Segment Softness In Its Investment Story?

Arrow Electronics' recent Akamai partnership aims to boost its higher-margin cybersecurity and cloud revenues, contrasting with ongoing softness in its Global Enterprise Computing Solutions segment. While the partnership highlights Arrow's role in higher-value tech, its near-term investment narrative remains heavily reliant on the recovery …

Arrow Electronics (NYSE:ARW) Downgraded by Zacks Research to Hold

Zacks Research has downgraded Arrow Electronics (NYSE:ARW) from a "strong-buy" to a "hold" rating. This adjustment comes despite the company reporting strong quarterly results, with EPS of $5.22 exceeding estimates and revenue up 39% year-over-year. The board also authorized a $1 billion share-repurchase program, …

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

Arrowhead Pharmaceuticals has acquired an FDA Rare Pediatric Disease Priority Review Voucher to accelerate the review process for its upcoming Supplemental New Drug Application (sNDA) for plozasiran. This sNDA aims to expand the approved indication of plozasiran, currently marketed as REDEMPLO, to include patients …

ARW.GB Bond Profile — Key Metrics

This article provides key metrics for the ARW.GB bond, an Arrow Electronics, Inc. 7.5% bond maturing on January 15, 2027. It details the issuer's business segments, such as Global Components Business and Global Enterprise Computing Solutions, and lists key financial facts including its issue …

Why Arrow Financial (AROW) is a Great Dividend Stock Right Now

Arrow Electronics (ARW) To Report Earnings Tomorrow: Here Is What To Expect

FDA voucher could put Arrowhead's planned drug filing on a six-month review track

Arrowhead Pharmaceuticals has acquired a Rare Pediatric Disease Priority Review Voucher (PRV) from an undisclosed third party. The company plans to use this voucher to expedite the FDA review of its Supplemental New Drug Application (sNDA) for plozasiran, aimed at treating severe hypertriglyceridemia (sHTG), …

Arrowstreet Capital Limited Partnership Grows Position in Arrow Financial Corporation $AROW

Arrowstreet Capital Limited Partnership significantly increased its stake in Arrow Financial Corporation (NASDAQ:AROW) by 71.6% in the first quarter, now holding 114,449 shares valued at $3.84 million. Despite this, the company reported quarterly EPS and revenue below consensus estimates. Arrow Financial also announced a …

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results

Arrowhead Pharmaceuticals Q3 Earnings Call Highlights

Arrowhead Pharmaceuticals reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), leading to plans for a supplemental New Drug Application. The company also highlighted continued growth in its REDEMPLO therapy for familial chylomicronemia syndrome (FCS), with prescription volumes more than doubling. Despite …

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals announced its fiscal 2026 third-quarter results, highlighting significant progress in its commercial product REDEMPLO and its robust R&D pipeline. Key achievements include the strong momentum of REDEMPLO's U.S. launch and new marketing authorizations in Europe and Australia, positive topline results for plozasiran …

Arrow Electronics to Post Q2 Results: What's in Store for the Stock?

Arrow Electronics (ARW) is set to release its Q2 2026 earnings on August 6, with sales estimated between $9.15 billion and $9.75 billion, a significant increase from the prior year. The company expects strong GAAP and non-GAAP earnings per share, having consistently surpassed consensus …

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - August 3, 2026

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that its Board of Directors approved inducement grants for 95 new employees on July 16, 2026. These grants, totaling up to 112,794 restricted stock units, fall under NASDAQ Listing Rule 5635(c)(4) and are separate from stockholder-approved equity incentive plans, …

Arrow Electronics, Inc. $ARW Shares Acquired by Amundi

Amundi significantly increased its stake in Arrow Electronics (NYSE:ARW) by 83.3% in the first quarter, now holding 209,973 shares valued at $30.1 million. This comes as institutional investors collectively own 99.34% of the company, and analysts maintain a "Moderate Buy" rating with an average …

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone

Arrowhead Pharmaceuticals announced positive Phase 3 results for plozasiran in severe hypertriglyceridemia and completed enrollment for the zodasiran Phase 3 trial. These developments bolster the company's cardiometabolic RNAi pipeline, potentially diversifying future revenue and broadening treatment options for lipid disorders. The strong clinical data …

Empowered Funds LLC Has $5.30 Million Stock Holdings in Arrow Electronics, Inc. $ARW

Empowered Funds LLC significantly increased its stake in Arrow Electronics, Inc. by 306.8% in the first quarter, now holding 36,928 shares valued at approximately $5.30 million. Institutional investors collectively own 99.34% of the company, which recently reported strong quarterly earnings and issued optimistic guidance. …

ArrowMark Financial Corp. (BANX) Q4 2022 Earnings: EPS Narrowly Misses Estimates as Credit Portfolio Holds Up

Arrow Electronics, Inc. Revenue Breakdown – NYSE:ARW

This article provides a revenue breakdown for Arrow Electronics, Inc. (NYSE: ARW), highlighting its top-performing segment and key regional contributions. Last year, the company generated $30.85 billion USD in revenue, with the Global Components segment accounting for $21.50 billion USD, and the United States …

Arrow Electronics (NYSE:ARW) Passes Minervini's Trend Template and High Growth Momentum Screen

Arrow Electronics (NYSE:ARW) has passed the Minervini's Trend Template and High Growth Momentum screen, indicating strong technical and fundamental alignment. The stock displays a confirmed Stage 2 uptrend with rising moving averages and high relative strength, supported by accelerating earnings and revenue growth. This …

Arrow Financial Corp (AROW) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of Arrow Financial Corp (AROW), noting its current financial score is 8.27, ranking 145 out of 395 in the Banking Services industry. While its financial status is weak, its operating efficiency is high, with a recent quarterly …

ArrowMark Financial Corp. Revenue Breakdown – NASDAQ:BANX

This article provides a revenue breakdown for ArrowMark Financial Corp. (NASDAQ: BANX), focusing on its top segments and regional performance. It highlights that the greatest contribution to the company's revenue came from the United States, which generated $17.18 million USD last year and $30.11 …

Arrow Financial Corp (AROW) discloses $1.12B across 281 positions in latest 13F

Arrow Financial Corp (AROW), an institutional investment manager, has filed its latest quarterly Form 13F holdings report, revealing equity holdings valued at $1.12 billion across 281 positions. The report also includes Arrow Bank National Association as another investment manager under the Arrow Financial umbrella. …

US042735BF63 Bond Profile — Key Metrics

This article provides a key metrics profile for the Arrow Electronics, Inc. bond US042735BF63. It details the bond's coupon rate, issue and maturity dates, outstanding amount, and face value. The profile also includes a brief description of Arrow Electronics, Inc.'s business segments.

Opaleye Management (NASDAQ: HROW) discloses 6.44% Harrow ownership in latest filing

Opaleye Management Inc., along with Opaleye, L.P. and James Silverman, has reported a beneficial ownership of 6.44% in Harrow, Inc.'s Common Stock, totaling 2,400,000 shares. This disclosure was made in a SCHEDULE 13G/A filing and is based on 37,275,107 shares outstanding as of May …

Vanguard unit discloses 6.38M Arrowhead (ARWR) shares, a 4.53% stake

Vanguard Portfolio Management LLC, along with its affiliates, has reported a beneficial ownership of 6,384,903 shares in Arrowhead Pharmaceuticals Inc. (ARWR), representing a 4.53% stake in the company. This disclosure, filed as a SCHEDULE 13G/A, indicates that Vanguard Portfolio Management has sole voting power …

Arrow Electronics, Inc. $ARW Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. significantly reduced its stake in Arrow Electronics (NYSE:ARW) by 52.6% in the first quarter, selling over 56,000 shares. Despite this, institutional investors and hedge funds still own a substantial 99.34% of the company, and Arrow Electronics reported strong quarterly earnings and …

Arrow Electronics, Inc. (NYSE:ARW) Given Average Rating of "Moderate Buy" by Brokerages

Arrow Electronics (NYSE:ARW) has received a "Moderate Buy" consensus rating from six brokerages, with an average 12-month price target of $222.00. The company recently reported strong quarterly results, beating earnings estimates with $5.22 per share and achieving $9.47 billion in revenue, a 39% year-over-year …

B. Riley Securities Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $123

B. Riley Securities has reiterated its Buy rating for Arrowhead Pharmaceuticals (ARWR.US) and increased the price target to $123. This adjustment reflects the firm's continued confidence in the company's financial prospects and market position.

Arrowhead Pharmaceuticals (ARWR) Could Be 3% Undervalued On Late Stage Trial Progress

Arrowhead Pharmaceuticals (ARWR) appears to be 3% undervalued, according to a recent analysis, following positive late-stage trial data for two RNA interference programs. The company's stock has seen significant momentum, with a 7x return over the past year, driven by reassessments of its risk …

Do Harrow’s (HROW) Retina Data Updates Quietly Redefine Its Core Growth Strategy?

Renaissance Technologies LLC Boosts Stock Position in Arrow Electronics, Inc. $ARW

Renaissance Technologies LLC increased its stake in Arrow Electronics (NYSE:ARW) by 3.6% in the first quarter, bringing its total holdings to 168,957 shares valued at $24.2 million. This comes as Arrow Electronics reported strong quarterly earnings, beating analyst expectations with $5.22 EPS and $9.47 …